Showing 7531-7540 of 9758 results for "".
- Suneva Medical: Bellafill Study is Largest, Longest Post-market Clinical Evaluation of Dermal Fillerhttps://practicaldermatology.com/news/suneva-medical-bellafill-study-is-largest-longest-post-market-clinical-evaluation-of-dermal-filler/2458874/Billed as the largest and longest post-market clinical evaluation of a dermal filler, a new study reported by Suneva Medical shows high levels of patient satisfaction and favorable safety outcomes with Bellafill five-years post-treatment. With an 87 percent retention rate, the study showed that a
- FDA Approves Humira for Moderate to Severe Hidradenitis Suppurativahttps://practicaldermatology.com/news/fda-approves-humira-for-moderate-to-severe-hidradenitis-suppurativa/2458873/The FDA approved AbbVie’s HUMIRA® (adalimumab) for the treatment of moderate to severe hidradenitis suppurativa (HS). HUMIRA is now the first and only FDA-approved therapy for adults with HS. Earlier this year, the FDA granted HUMIRA orphan drug designation for t
- ASDS Survey Finds Consumers Prefer Its Membershttps://practicaldermatology.com/news/asds-survey-finds-consumers-prefer-its-members/2458882/The 2015 American Society for Dermatologic Surgery (ASDS) Consumer Survey on Cosmetic Dermatologic Procedures – which reflects views on cosmetic medical treatments and ratings for 10 specific procedures – shows the majority of respondents in eight of 10 categories who had visited a de
- AAD Releases Second Set of Choosing Wisely Recommendationshttps://practicaldermatology.com/news/aad-releases-second-set-of-choosing-wisely-recommendations/2458884/The American Academy of Dermatology (AAD) released its second set of recommendations regarding dermatologic tests and treatments that are not always necessary. These recommendations were developed as part of the
- Costs, Uncertainty May Cause Consumers to Delay Cosmetic Procedures: ASDShttps://practicaldermatology.com/news/costs-uncertainty-may-cause-consumers-to-delay-cosmetic-procedures-asds/2458886/Cost, fear of suboptimal results, and uncertainty over choosing a provider are the key concerns that may deter prospective patients from receiving cosmetic treatments, new findings from the 2015 American Society for Dermatologic Surgery Consumer Survey on Cosmetic Dermatologic Procedures sh
- Simulated Patient Encounter Part of Summer AAD Programhttps://practicaldermatology.com/news/simulated-patient-encounter-part-of-summer-aad-program/2458888/Simulated patient encounters have come to the American Academy of Dermatology's summer meeting, offering a unique, hands-on educational experience for attendees. Speaking to Seemal Desai, MD for DermTube.com's coverage of the 2015 Summer Meeting of the AAD in New York City, Kanade Shinkai
- Provectus Receives Patent for Investigational Melanoma Agent PV-10https://practicaldermatology.com/news/provectus-receives-patient-for-investigational-melanoma-agent-pv-10/2458891/Provectus Biopharmaceuticals, Inc. has received a patent from the US Patent and Trademark Office, protecting the use of PV-10 in combination with certain other types of drugs in the treatment of melanoma and cancers of the liver. Specifically, the patent covers the use of PV-10 in combination wit
- MEG 21 with Supplamine Now Available in Treatment Rooms with New Professional Size Dispensershttps://practicaldermatology.com/news/meg-21-with-supplamine-now-available-in-treatment-rooms-with-new-professional-size-dispensers/2458892/MEG 21 with Supplamine is a science-based company specializing in skin products for the face, neck, décolleté, and arms that uniquely remove toxic sugar from skin. Dynamis Skin Science, the parent company, was founded in 1997, based on the work of scientists initially working at Fox
- LaserCap Receives 510(k) Clearance for Hair Treatment Devicehttps://practicaldermatology.com/news/lasercap-receives-510k-clearance-for-hair-treatment-device/2458894/LaserCap® Company has received FDA 510(k) clearance for the
- Finacea Foam 15% Approved for Treatment of Inflammatory Papules and Pustules in Patients with Mild to Moderate Rosaceahttps://practicaldermatology.com/news/finacea-foam-15-approved-for-treatment-of-inflammatory-papules-and-pustules-in-patients-with-mild-to-moderate-rosacea/2458899/The FDA approved Finacea® (azelaic acid) Foam, 15% for the topical treatment of the inflammatory papules and pustules of mild to moderate rosacea. The approval is based on results from two pivotal clinical trials examining the efficacy and safety of Finacea® Foam com